BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application
XOMA Corporation (XOMA)
Last xoma corporation earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xoma.com/investor-relations
Company Research
Source: PR Newswire
LUND, Sweden, July 4, 2019 /PRNewswire/ -- BioInvent International AB (BINV) today announced it will receive a $0.5 million milestone payment related to the acceptance by the U.S. Food and Drug Administration of the Investigational New Drug (IND) application for TAK-169, a first-in-class CD38-targeted fusion protein. The IND was filed by Takeda Pharmaceutical Company Limited under a co-development agreement with Molecular Templates. This milestone relates to BioInvent's proprietary n-CoDeR® antibody library and its role in the discovery of the investigational compound. Takeda is developing TAK-169 under a royalty and milestone agreement with XOMA Corporation (NASDAQ: XOMA). BioInvent and XOMA have a long-standing cross-licensing agreement covering BioInvent's proprietary n-CoDeR® antibody library and XOMA's bacterial protein expression technology. Martin Welschof, CEO of BioInvent, said, "This is validating that our n-CoDeR® platform not only yields highly promising drug candidates fo
Show less
Read more
Impact Snapshot
Event Time:
XOMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XOMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XOMA alerts
High impacting XOMA Corporation news events
Weekly update
A roundup of the hottest topics
XOMA
News
- XOMA Co. (NASDAQ: XOMA) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
- XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.MarketBeat
- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% [Yahoo! Finance]Yahoo! Finance
- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%GlobeNewswire
- XOMA Co. (NASDAQ: XOMA) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $40.00 price target on the stock.MarketBeat
XOMA
Earnings
- 11/7/23 - Miss
XOMA
Sec Filings
- 4/30/24 - Form 8-K
- 4/25/24 - Form 8-K
- 4/3/24 - Form 8-K
- XOMA's page on the SEC website